Research

Hormonal

The effect of Tirzepatide on Fat-Free Mass (FFM) is inconclusive and potentially adverse, with some studies showing greater FFM loss compared to other anti-obesity drugs, particularly at higher doses.

While Tirzepatide is excellent for fat loss, patients should be aware that it may also cause a loss of lean muscle mass, potentially more than other similar drugs. To mitigate this, combining TZP treatment with resistance training and adequate protein intake is crucial, although clinical data on optimizing FFM preservation with TZP is currently lacking.

ModerateQualifiesMEDIUM confidence
the effect of TZP on fat-free mass (FFM) is still uncertain because the findings remain inconclusive... TZP seems to determine a higher reduction/deterioration in FFM compared to that of other medications (dulaglutide and semaglutide) by nearly 0.8–2 kg, which appears to occur at the highest dose of TZP (i.e., 15 mg)
Mariona Masgrau Juanola et al. · Aula de innovación educativa · 2012

Why this rating

Findings are inconsistent across small samples and different measurement methods (BIA vs DXA).

Source

De las ideas a los proyectos : la creatividad como pilar básico del emprendimiento

Mariona Masgrau Juanola et al. · Aula de innovación educativa · 2012

DOI 10.3390/diseases12090204

systematic_review · n=3443Cited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →